awmsg logo



chlormethine (Ledaga®)


Reference No. 1566

Publication date:
13/07/2017


Appraisal information

chlormethine (Ledaga®) 160 µg/g gel


Company: Actelion Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 12/07/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, chlormethine (Ledaga®) cannot be endorsed for use within NHS Wales for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.
Statement of Advice (SOA)
Download